| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Division of Medical Sciences, Endocrinology, Institute of Biomedical Research, Medical School, University of Birmingham, Birmingham, B15 2TT, UK
1 Endocrine Unit, Molecular Medicine Centre, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK
2 Paediatrics, University of Texas Southwestern Medical Center, Harry Hines Boulevard, Dallas, TX, USA
(Requests for offprints should be addressed to P M Stewart; Email: p.m.stewart{at}bham.ac.uk)
* (N Draper and Z Michailidou contributed equally to this work) 
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and methodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
11ß-HSD1-mediated oxo-reductase activity in liver and adipose tissue may modulate development of the metabolic syndrome. Exposure to cortisol increases hepatic glucose output (Jones et al. 1993) and adipocyte differentiation (Hauner et al. 1987). Selective inhibitors have shown beneficial results in improving insulin sensitivity and causing weight loss (Alberts et al. 2003, Livingstone & Walker 2003), but the factors determining oxo-reductase activity per se have remained elusive.
Hexose-6-phosphate dehydrogenase (H6PDH, EC 1.1.1.47 [EC] ) performs the first two steps of a pentose phosphate pathway which is believed to exist within the ER lumen (Bublitz & Steavenson 1988). It is responsible for converting glucose-6-phosphate to 6-phospho-gluconolactone, thereby generating NADPH (Kimura et al. 1979, Stegeman & Klotz 1979). Based on genetic evidence, we have argued that reduced H6PDH activity, together with reduced expression of 11ß-HSD1, underlies cortisone reductase deficiency (CRD). Women affected with CRD have polycystic ovary syndrome (PCOS) with menstrual irregularity, hirsutism and infertility. They are unable to generate cortisol from cortisone due to defective 11ß-HSD1 oxo-reductase activity (Nikkila et al. 1993, Jamieson et al. 1999) resulting in activation of the hypothalamic–pituitary–adrenal axis and adrenocorticotrophin (ACTH) driven adrenal androgen excess (Biason-Lauber et al. 2000, Laing et al. 2002). These patients carry coding-sequence mutations in the gene encoding H6PDH (H6PD) in association with intronic mutations in the 11ß-HSD1 gene (HSD11B) that reduce gene transcription (Draper et al. 2003).
Here we show that H6PDH has the potential to profoundly influence 11ß-HSD1 by affecting the reaction direction in intact cells and also demonstrate that in primary cultures of human omental preadipocytes, levels of H6PDH expression predict oxo-reductase activity.
|
Materials and methods |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
Omental adipose tissue biopsies were obtained from 15 female patients undergoing elective abdominal surgery (median age 40 years, range 28–60 years, median body mass index (BMI) 29.3 kg/m2, range 19.7–39.2). All gave their full informed, written consent. The study had the approval of the local research ethics committee.
Primary culture
Omental preadipocytes were isolated as previously reported (Bujalska et al. 1997b), seeded in a 24-well tissue culture dish and cultured to confluence (up to 6 days) in DMEM/F12 media supplemented with 10% fetal calf serum. At this point, 11ß-HSD1 oxo-reductase assays were performed, protein concentration measured and total RNA extracted. In a further set of experiments, omental preadipocytes were isolated from adipose tissue obtained at elective surgery (n=12). Preadipocytes were differentiated into mature adipocytes according to an established protocol (Hauner et al. 1987). Briefly, after cell washing (day 1), 11ß-HSD1 oxo-reductase and dehydrogenase activities were measured and total RNA extracted. Cells were then differentiated for a further 14 days, 11ß-HSD1 activity measured, total RNA extracted and H6PDH and 11ß-HSD1 expression measured by real-time PCR as described below.
Transient transfection of chinese hamster ovary (CHO) cells
Full length cDNA encoding rat 11ß-HSD1 was subcloned into pDR2 (Clontech). The pDR2 derivative encoding human 11ß-HSD2 cDNA has been previously described (Brown et al. 1996). The coding region of human H6PDH cDNA (Mason et al. 1999) was subcloned into pcDNA3.1 (Invitrogen). PBADHuG6PD, encoding human G6PD (Persico et al. 1986), was kindly provided by Dr P Mason (Imperial College, London, UK). Chinese hamster ovary (CHO) cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 µg/mL streptomycin. Twenty-four hours prior to transfection, CHO cells were seeded at 2x105 cells/60 mm dish and transfected with a total of 21 µg DNA using the calcium phosphate procedure (Voice et al. 1996). DNA consisted of 10 µg pDR2 vector or 11ß-HSD expression plasmid, 10 µg pcDNA3.1, H6PDH or pBADHuG6PD plasmid and 1 µg pCH110 (Amersham) encoding ß-galactosidase; the last plasmid was an internal control for transfection efficiency. In each experiment, transfections were independently carried out in sextuplet; three for each assay of 11ß-HSD activity in oxo-reductase or dehydrogenase direction after adding 3H-steroid to the medium 2 h after transfection. Forty two hours after transfection, cells were lysed and ß-galactosidase activity assayed, as previously described (Williams et al. 2000), to verify that transfection efficiency was similar between transfections.
siRNA experiments
HEK 293T1 cells were used for siRNA transfection. They were derived from human embryonic kidney cells (HEK 293) by stable transfection with human 11ß-HSD1 cDNA in the vector pCR3 (Invitrogen, UK) and display both dehydrogenase and oxo-reductase activities (Bujalska et al. 1997a). Cells were plated at 3.0x104 cells per well in a 24-well tissue culture plate. Following 24 h in culture, cells were transfected with 100 nM H6PDH siRNA (Ambion siRNA ID 14371), 11ß-HSD1 siRNA (Ambion siRNA ID 16305), or SilencerTM Negative Control #1 siRNA (Ambion, Huntingdon, Cambs, UK) using 3 µl per well siPORT Amine Transfection Agent (Ambion) according to the manufacturer’s protocol. Forty eight hours after transfection, 11ß-HSD1 assays were performed as described below and the cells were subsequently harvested for protein and total RNA. H6PDH and 11ß-HSD1 mRNA levels were measured by real-time RT-PCR with 18S rRNA as the internal standard. Target gene expression was calculated as fold change compared with the negative control siRNA gene expression. All experiments were carried out in triplicate.
RNA extraction and reverse transcription
Total RNA was extracted using a single step extraction method (Tri Reagent, Sigma). One microgram of total RNA was reverse transcribed using random hexamers in 20 µl volume according to manufacturer’s protocol (Promega).
Real-time PCR
11ß-HSD1 and H6PDH mRNA levels were measured by real-time PCR using an ABI 7700 system (Perkin-Elmer, Biosystems, Warrington, UK). PCR was performed in 25 µl reactions on 96-well plates. Reactions contained TaqMan universal PCR master mix (Applied Biosystems, Warrington, Cheshire, UK), 900 nmol primers, 100–200 nmol TaqMan probe and 25–50 ng cDNA. All reactions were multiplexed with primers specific for 18S rRNA (provided as a pre-optimized mix; Perkin-Elmer, Beaconsfield, Bucks, UK) as an internal reference. All target gene probes were labeled with the fluorescent label FAM, and the 18S probe with the fluorescent label VIC. Reactions were as follows: 50 °C for 2 min, 95 °C for 10 min, and then 44 cycles of 95 °C for 15 sec and 60 °C for 1 min. Data were analyzed according to the manufacturer’s guidelines and were obtained as Ct values (the cycle number at which logarithmic PCR plots cross a calculated threshold line) and used to determine dCt values (dCt=Ct of the target gene minus Ct of the internal reference, 18S).
Sequences of oligonucleotide primers and probes for 11ß-HSD1 and H6PDH were as follows; 11ß-HSD1: forward 5'-AGGAAAGCTCATGGGAGGACTAG-3', reverse 5'-ATGGTGAATATCATCATGAAAAAGA TTC-3', and probe 5'-CATGCTCATTCTCAACCAC ATCACCAACA-3'. H6PDH: forward 5'-AGAACT CGGGACCTTTTTCCA-3', reverse 5'-GCGCCACA GCCTGCTT-3', and probe 5'-TAAGTAATGGT CCACCCGGTACATCTCCTCC-3'.
Western blot analysis
Twenty micrograms of protein from cell lysates (siRNA experiments) was analysed by SDS-PAGE using 12.5% gels on a Bio-Rad Mini-Protean II apparatus (Bio-Rad, Richmond, CA, USA). Ten micrograms of human liver homogenate, produced as previously reported (Ricketts et al. 1998), was loaded as a control. Western blotting was performed as reported previously (Ricketts et al. 1998). Membranes were incubated with validated polyclonal antibody to human 11ß-HSD1 (The Binding Site, Birmingham, UK) at a dilution of 1:1000 for 16 h at 4 °C. Following 3x10 min washes in PBS-containing 0.1% Tween 20, membranes were incubated with secondary antibody (goat anti-sheep IgG peroxidase conjugate; The Binding Site, Birmingham, UK) at a dilution of 1:75 000 for 1.5 h at room temperature. Bound peroxidase-conjugated Ig was visualized using ECL detection kit (Amersham Pharmacia Biotech, Buckinghamshire, UK) by exposing membranes to X-ray film (Kodak).
11ß-hydroxysteroid dehydrogenase assay
Assays of 11ß-HSD1 activity were performed by incubating intact cells with 1 ml of serum-free culture media with 100 nM cortisone (oxo-reductase) or cortisol (dehydrogenase) and tritiated tracer for 3–16 h, or (for transfected CHO cells) with 25 nM corticosterone or 11-dehydrocorticosterone for 42 h. After incubation, media was transferred to a glass tube and steroids were extracted with 5 ml of dichloromethane. Next the aqueous phase was removed and dichloromethane phase concentrated to 100 ul which was then spotted on a TLC silica plate. Steroids were separated by thin layer chromatography using a mobile phase of ethanol and chloroform (8:92) and quantitated using a Bioscan 2000 image analyzer (Lablogic, Sheffield, UK) or a phosphorimager (Fuji FLA-2000, Raytek Scientific Ltd, Sheffield, UK). Protein levels were assayed using a 96-well plate assay kit (Bio-Rad Laboratories Inc., Hercules, CA, USA). All experiments were carried out in triplicate.
Data analysis
Values are given as means±S.E. of (n) separate experiments. Statistical analysis of comparisons among groups was undertaken using the one-way analysis of variance (for normal distribution) or Mann–Whitney rank sum test (for non-normal distribution). Non-parametric Spearman correlation has been used to analyze preadipocyte data. P values of less than 0.05 were accepted as statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
In transfected cell lines, 11ß-HSD1 is predominantly an oxo-reductase (Low et al. 1994). The important exception to this is CHO cells, in which transiently transfected 11ß-HSD1 encodes both oxo-reductase and dehydrogenase activities at approximately equal levels (Agarwal et al. 1989). Co-transfection of CHO cells with an expression plasmid encoding H6PDH together with an 11ß-HSD1 plasmid increased oxo-reductase activity compared with controls transfected with 11ß-HSD1 plasmid and empty pcDNA3.1 vector; 68.7±3.0 vs 42.4±2.4% respectively, P<0.05 (Fig. 1A
). Simultaneously, dehydrogenase activity was virtually eliminated; 4.0±0.7 vs 27.2±1.9% in controls, P<0.05 (Fig. 1B). In contrast, H6PDH had no effeect on reaction direction of 11ß-HSD2; 0.8±0.3% vs 1.2±0.5% in controls (oxo-reductase) and 97.5±1.6% vs 91.0±5.2% in controls (dehydrogenase) (Figs 1A and B). Furthermore co-transfection of CHO cells with an expression plasmid encoding the cytosolic enzyme G6PD failed to produce any differences in oxo-reductase (32.7±2.4% vs controls 42.4±2.4%) or dehydrogenase (19.0±1.2% vs controls 27.2±1.9%) activities (Figs 1A and B).
|
Introduction of either 11ß-HSD1 or H6PDH siRNA in HEK 293T1 cells caused a significant decrease in the target mRNA levels compared with cells transfected with a control/scrambled siRNA (Silencer Negative Control #1); 11ß-HSD1 mRNA fold change: 0.48±0.07, n=6, P<0.01, H6PDH mRNA fold change: 0.46±0.12, n=6, P<0.01, (Fig. 2A). Furthermore, 11ß-HSD1 protein levels were significantly decreased in cells transfected with 11ß-HSD1 siRNA compared with cells transfected with H6PDH siRNA or a scrambled siRNA control (Fig. 2B). Both 11ß-HSD1 dehydrogenase and oxo-reductase activities were similarly decreased in intact cells from 11ß-HSD1 siRNA-transfected cells compared with scrambled siRNAs: dehydrogenase; 0.64±0.11, n=6, P<0.001, and oxo-reductase; 0.85±0.14, n=6, P<0.05 (Fig. 2C).
|
), but did cause a significant decrease in oxo-reductase activity in intact cells compared with cells transfected with scrambled siRNA; fold change 0.81±0.13, n=6, P<0.05, (Fig. 2C). Of note, 11ß-HSD1 dehydrogenase activity was concomitantly increased by transfection with H6PDH siRNA, fold change 1.11ß0.09, n=6, P<0.05 (Fig. 2C). Correlation between 11ß-HSD1 activity and H6PDH expression in human omental preadipocytes
To investigate whether H6PDH similarly regulates 11ß-HSD1 reaction direction in intact primary cultures endogenously expressing 11ß-HSD1, oxo-reductase activity and H6PDH mRNA levels were assayed in human omental preadipocytes. Significant oxo-reductase activity was seen in all cultured preadipocyte preparations.
A significant (P<0.05) negative correlation between dCt for H6PDH [Median 11.04; 10.64 (25%), 11.6 (75%) CI] and 11ß-HSD1 oxo-reductase activity [Median 37.0; 21.02 (25%), 59.60 (75%) CI] in omental human preadipocytes was observed. This illustrates a positive correlation between H6PDH mRNA and 11ß-HDS1 oxo-reductase activity. To present the positive directionality of the correlation, H6PDH mRNA levels have been expressed as –dCt, and its relation with 11ß-HSD1 oxo-reductase has been shown in Fig. 3A. The change in 11ß-HSD1 oxo-reductase levels occurred despite no significant difference in 11ß-HSD1 mRNA levels (dCt: 12.34±0.25, mean±S.E.).
|
), but importantly no correlation between BMI and 11ß-HSD1 mRNA levels (P=0.18) (data not shown).
Moreover, H6PDH mRNA levels inversely correlated with BMI as reflected by a positive correlation (P=0.012) between dCt for H6PDH expression [Median 11.04; 10.64 (25%), 11.6 (75%) CI] and BMI [Median 29.3; 26.2 (25%), 33.1 (75%) CI]. Again, H6PDH mRNA levels have been expressed as –dCt and the correlation between –dCt and BMI has been shown in Fig. 3C.
Across adipocyte differentiation, 11ß-HSD1 oxo-reductase activity increased (11.8±3.6 vs 66.1±21.9 pmol/mg/h, day 1 vs day 14, P<0.05) whilst dehydrogenase activity decreased (104.0±25.1 vs 17.3±5.0 pmol/mg/h, day 1 vs day 14, P<0.01), (Fig. 4A). Concomitantly, H6PDH mRNA levels increased 5.3-fold as measured by quantitative real-time PCR (dCt 13.5±0.7 vs 11.5±0.5, day 1 vs day 14, P<0.05) (Fig. 4B). There was no significant difference in 11ß-HSD1 mRNA expression during omental preadipocytes differentiation (Fig. 4B).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
Here we show unequivocally that H6PDH is able to regulate 11ß-HSD1 enzyme direction. Co-expression of 11ß-HSD1 with H6PDH in CHO cells increased oxo-reductase activity whilst reducing dehydrogenase activity. A parallel study (Atanasov et al. 2004) also showed a 6-fold increase in oxo-reductase with simultaneous 6-fold decrease in dehydrogenase in transiently transfected HEK 293 cells with 11ß-HSD1 and H6PDH, confirming our earlier concept of a close inter-relationship between these two enzymes within the ER. In this study, we have further shown the specificity of 11ß-HSD1 for H6PDH, since co-transfection with a cytosolic NADPH-provider, G6PD, failed to modulate 11ß-HSD1 reaction direction. In contrast, the overwhelmingly oxidative reaction direction of 11ß-HSD2 was unaffected by co-transfection with H6PDH, as predicted given that the active site of this enzyme faces toward the cytosol (Naray-Fejes-Toth & Fejes-Toth 1996). This finding is indicative of a pool of co-factors localized within the ER lumen, separated from the cytosolic compartment.
Additionally, we have further endorsed these findings through siRNA ‘knock-down’ experiments in HEK 293T1 cells, where a 50% reduction in 11ß-HSD1 or H6PDH mRNA expression was achieved. Reduction in 11ß-HSD1 mRNA altered dehydrogenase and oxo-reductase activities to a similar degree, with the concurrent decrease in 11ß-HSD1 protein expression. Silencing of H6PDH, however, preferably reduced oxo-reductase activity whilst increasing dehydrogenase activity.
Here, we have shown an increase in oxo-reductase 11ß-HSD1 activity and H6PDH expression in differentiating human omental preadipocytes. In a parallel study, using the 3T3-L1 mouse cell line, a modest increase in H6PDH mRNA levels has been shown to occur across adipogenesis, associated with a highly significant increase in 11ß-HSD1 oxo-reductase activity (Atanasov et al. 2004). However, in this cell system, levels of 11ß-HSD1 mRNA also increased more than 100-fold across adipogenesis. This alone could have accounted for the observed significant increase in 11ß-HSD1 oxo-reductase activity which is not the case in our human cell model where the increase in 11ß-HSD1 oxo-reductase occurred despite unchanged levels of 11ß-HSD1 expression.
In addition, in this study, we demonstrate that expression H6PDH mRNA levels decreased with increasing BMI, perhaps explaining the observed decrease in 11ß-HSD1 oxo-reductase activity in omental preadipocytes in obese patients (Tomlinson et al. 2002). Our earlier studies have shown that glucocorticoids inhibit preadipocyte proliferation (Tomlinson et al. 2002); thus the impaired oxo-reductase activity may increase the number of proliferating preadipocytes in visceral depots. Because 11ß-HSD1 mRNA levels in human omental adipose tissue are poorly correlated with BMI (Tomlinson et al. 2002), we hypothesize that the ‘set-point’ of 11ß-HSD1 reaction direction may be contributing more to the pathogenesis of central obesity than its absolute expression levels. On this note, it is interesting to speculate that earlier studies that inferred increased oxo-reductase activity in obese subjects, based upon an increase in measured dehydrogenase activity, might not represent the in vivo situation as this reflects the amount of enzyme present but not its directionality (Rask et al. 2001, Wake et al. 2003). To summarize, in this study we now demonstrate a direct relationship between 11ß-HSD1 oxo-reductase activity and H6PDH expression in human omental preadipocytes and cell line models.
In terms of human disease, the targeted inhibition of 11ß-HSD1 as a therapeutic strategy in patients with the metabolic syndrome is an exciting advance (Alberts et al. 2002, Andrews et al. 2003, Sandeep et al. 2004, Rauz et al. 2003). In turn, the identification of H6PDH as a determinant of oxo-reductase activity in adipose tissue raises the possibility that H6PDH itself could be a promising therapeutic target in treating central obesity. Indeed it is tempting to speculate that some of the ‘selective 11ß-HSD1' inhibitors obtained through cell-based high throughput screening assays, might actually be inhibitors of H6PDH rather than 11ß-HSD1.
|
Acknowledgements |
|---|
This work was funded by an MRC co-operative core grant and by the Wellcome Program Fund (WT065998/Z/01Z). P White is supported by the Audry Newman Rapoport Distinguished Chair in Pediatric Endocrinology. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.
|
References |
|---|
|
TopAbstractIntroductionMaterials and methodsResultsDiscussionReferences |
|---|
Agarwal AK, Tusie-Luna MT, Monder C & White PC 1990 Expression of 11ß-hydroxysteroid dehydrogenase using recombinant vaccinia virus. Molecular Endocrinology 4 1827–1832.[Abstract]
Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G, Larsson C, Ronquist-Nii Y, Ohman B & Abrahmsen L 2002 Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45 1528–1532.[CrossRef][ISI][Medline]
Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingstrom G, Larsson C, Forsgren M, Ashkzari M et al. 2003 Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144 4755–4762.
Andrews RC, Rooyackers O & Walker BR 2003 Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 88 285–291.
Atanasov AG, Nashev LG, Schweizer RA, Frick C & Odermatt A 2004 Hexose-6-phosphate dehydrogenase determines the reaction direction of 11 beta-hydroxysteroid dehydrogenase type 1 as an oxoreductase. FEBS Letters 571 129–133.[CrossRef][ISI][Medline]
Banhegyi G, Benedetti A, Fulceri R & Senesi S 2004 Cooperativity between 11 bbeta -hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase in the lumen of the endoplasmic reticulum. Journal of Biological Chemistry 25 27017–27021.
Beutler E & Morrison M 1967 Localization and characteristics of hexose 6-phosphate dehydrogenase (glucose dehydrogenase). Journal of Biological Chemistry 242 5289–5293.
Biason-Lauber A, Suter SL, Shackleton CH & Zachmann M 2000 Apparent cortisone reductase deficiency: a rare cause of hyperandrogenemia and hypercortisolism. Hormone Research 53 260–266.[CrossRef][ISI][Medline]
Bland R, Worker CA, Noble BS, Eyre LJ, Bujalska IJ, Sheppard MC, Stewart PM & Hewison M 1999 Characterization of 11 beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines. Journal of Endocrinology 161 455–464.[Abstract]
Brown RW, Chapman KE, Kotelevtsev Y, Yau JL, Lindsay RS, Brett L, Leckie C, Murad P, Lyons V, Mullins JJ et al. 1996 Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2. Biochemical Journal 313 1007–1017.
Bublitz C & Steavenson S 1988 The pentose phosphate pathway in the endoplasmic reticulum. Journal of Biological Chemistry 263 12849–12853.
Bujalska I, Shimojo M, Howie A & Stewart PM 1997a Human 11 beta-hydroxysteroid dehydrogenase: studies on the stably transfected isoforms and localization of the type 2 isozyme within renal tissue. Steroids 62 77–82.[CrossRef][ISI][Medline]
Bujalska IJ, Kumar S & Stewart PM 1997b Does central obesity reflect ‘Cushing’s disease of the omentum’? Lancet 349 1210–1213.[CrossRef][ISI][Medline]
Bujalska IJ, Kumar S, Hewison M & Stewart PM 1999 Differentiation of adipose stromal cells: the roles of glucocorticoids and 11 beta-hydroxysteroid dehydrogenase. Endocrinology 140 3188–3196.
Bujalska IJ, Walker EA, Hewison M & Stewart PM 2002 A switch in dehydrogenase to reductase activity of 11 beta-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. Journal of Clinical Endocrinology and Metabolism 87 1205–1210.
Cooper MS, Walker EA, Bland R, Fraser WD, Hewison M & Stewart PM 2000 Expression and functional consequences of 11 beta-hydroxysteroid dehydrogenase activity in human bone. Bone 27 375–381.[Medline]
Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, Lavery GG, Bedendo O, Ray DW, Laing I et al. 2003 Mutations in the genes encoding 11 beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nature Genetics 34 434–439.[CrossRef][ISI][Medline]
Ge RS, Gao HB, Nacharaju VL, Gunsalus GL & Hardy MP 1997 Identification of a kinetically distinct activity of 11 beta-hydroxysteroid dehydrogenase in rat Leydig cells. Endocrinology 138 2435–2442.
Gerin I & Van Schaftingen E 2002 Evidence for glucose-6-phosphate transport in rat liver microsomes. FEBS Letters 517 257–260.[CrossRef][ISI][Medline]
Hauner H, Schmid P & Pfeiffer EF 1987 Glucocorticoids and insulin promote the differentiation of human adipocyte precursor cells into fat cells. Journal of Clinical Endocrinology and Metabolism 64 832–835.[Abstract]
Jamieson PM, Chapman KE, Edwards CR & Seckl JR 1995 11 beta-hydroxysteroid dehydrogenase is an exclusive 11 beta-reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 136 4754–4761.[Abstract]
Jamieson A, Wallace AM, Andrew R, Nunez BS, Walker BR, Fraser R, White PC & Connell JM 1999 Apparent cortisone reductase deficiency: a functional defect in 11 beta- hydroxysteroid dehydrogenase type 1. Journal of Clinical Endocrinology and Metabolism 84 3570–3574.
Jamieson PM, Walker BR, Chapman KE, Andrew R, Rossiter S & Seckl JR 2000 11 beta-hydroxysteroid dehydrogenase type 1 is a predominant 11 beta-reductase in the intact perfused rat liver. Journal of Endocrinology 165 685–692.[Abstract]
Jellinck PH, Pavlides C, Sakai RR & McEwen BS 1999 11 beta-hydroxysteroid dehydrogenase functions reversibly as an oxidoreductase in the rat hippocampus in vivo. Journal of Steroid Biochemistry and Molecular Biology 71 139–144.[CrossRef][ISI][Medline]
Jones CG, Hothi SK & Titheradge MA 1993 Effect of dexamethasone on gluconeogenesis, pyruvate kinase, pyruvate carboxylase and pyruvate dehydrogenase flux in isolated hepatocytes. Biochemical Journal 289 821–828.
Kimura K, Endou H, Sudo J & Sakai F 1979 Glucose dehydrogenase (hexose 6-phosphate dehydrogenase) and the microsomal electron transport system. Evidence supporting their possible functional relationship. Journal of Biochemistry 85 319–326.
Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR et al. 1997 11 beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. PNAS 94 14924–14929.
Laing I, Adams JE, Wood PJ, Taylor NF & Ray DW 2002 Cortisone Reductase deficiency (11ß-hydroxysteroid dehydrogenase type 1) presenting with features of late onset congenital adrenal hyperplasia. Endocrine Abstracts 3 P264.
Lakshmi V & Monder C 1988 Purification and characterization of the corticosteroid 11ß- dehydrogenase component of the rat liver 11ß-hydroxysteroid dehydrogenase complex. Endocrinology l23 2390–2398.
Leckie CM, Welberg LA & Seckl JR 1998 11 beta-hydroxysteroid dehydrogenase is a predominant reductase in intact rat Leydig cells. Journal of Endocrinology 159 233–238.[Abstract]
Livingstone DE & Walker BR 2003 Is 11 beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. Journal of Pharmacology and Experimental Therapeutics 305 167–172.
Low SC, Chapman KE, Edwards CRW & Seckl JR 1994 Liver-type 11-beta-hydroxysteroid dehydrogenase cdna encodes reductase but not dehydrogenase-activity in intact mammalian cos-7 cells. Journal of Molecular Endocrinology 13 167–174.[Abstract]
Mason PJ, Stevens D, Diez A, Knight SW, Scopes DA & Vulliamy TJ 1999 Human hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) encoded at 1p36: coding sequence and expression. Blood Cells, Molecules and Diseases 25 30–37.[CrossRef][ISI][Medline]
Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR & Flier JS 2001 A transgenic model of visceral obesity and the metabolic syndrome. Science 294 2166–2170.
Monder C & Lakshmi V 1989 Evidence for kinetically distinct forms of corticosteroid 11ß-dehydrogenase in rat liver microsomes. Journal of Steroid Biochemistry 32 77–83.[CrossRef][ISI][Medline]
Monder C, Lakshmi V & Miroff Y 1991 Kinetic studies on rat liver 11 beta-hydroxysteroid dehydrogenase. Biochimica and Biophysica Acta 1115 23–29.[Medline]
Naray-Fejes-Toth A & Fejes-Toth G 1996 Subcellular localization of the type 2 11 beta-hydroxysteroid dehydrogenase. A green fluorescent protein study. Journal of Biological Chemistry 271 15436–15442.
Nikkila H, Tannin GM, New MI, Taylor NF, Kalaitzoglou G, Monder C & White PC 1993 Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency. Journal of Clinical Endocrinology and Metabolism 77 687–691.[Abstract]
Odermatt A, Arnold P, Stauffer A, Frey BM & Frey FJ 1999 The N-terminal anchor sequences of 11 beta-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. Journal of Biological Chemistry 274 28762–28770.
Ozols J 1993 Isolation and the complete amino acid sequence of lumenal endoplasmic reticulum glucose-6-phosphate dehydrogenase. PNAS 90 5302–5306.
Ozols J 1995 Lumenal orientation and post-translational modifications of the liver microsomal 11 beta-hydroxysteroid dehydrogenase. Journal of Biological Chemistry 270 2305–2312.
Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR & Mullins JJ 2004 Metabolic syndrome without obesity: Hepatic overexpression of 11 beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. PNAS 101 7088–7093.
Persico MG, Viglietto G, Martini G, Toniolo D, Paonessa G, Moscatelli C, Dono R, Vulliamy T, Luzzatto L & D’Urso M 1986 Isolation of human glucose-6-phosphate dehydrogenase (G6PD) cDNA clones: primary structure of the protein and unusual 5' non-coding region. Nucleic Acids Research 14 2511–2522.
Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O & Walker BR 2001 Tissue-specific dysregulation of cortisol metabolism in human obesity. Journal of Clinical Endocrinology and Metabolism 86 1418–1421.
Rauz S, Cheung CM, Wood PJ, Coca-Prados M, Walker EA, Murray PI & Stewart PM 2003 Inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension. Quarterly Journal of Medicine 96 481–490.
Rauz S, Walker EA, Shackleton CH, Hewison M, Murray PI & Stewart PM 2001 Expression and putative role of 11 beta-hydroxysteroid dehydrogenase isozymes within the human eye. Investigative Ophthalmology and Visual Science 42 2037–2042.
Rebuffe-Scrive M, Krotkiewski M, Elfverson J & Bjorntorp P 1988 Muscle and adipose tissue morphology and metabolism in Cushing’s syndrome. Journal of Clinical Endocrinology and Metabolism 67 1122–1128.[Abstract]
Ricketts ML, Verhaeg J, Bujalska I, Howie AJ, Rainey WE & Stewart PM 1998 Immunochistological Localization of Type 1 11ß-Hydroxysteroid Dehydrogenase in Human Tissues. Journal of Clinical Endocrinology and Metabolism 83 1325–1335.
Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, Walker BR & Seckl JR 2004 11 Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. PNAS 101 6734–6739.
Stegeman JJ & Klotz AV 1979 A possible role for microsomal hexose-6-phosphate dehydrogenase in microsomal electron transport and mixed-function oxygenase activity. Biochemical and Biophysical Research Communications 87 410–415.[CrossRef][ISI][Medline]
Stewart PM, Boulton A, Kumar S, Clark PM & Shackleton CH 1999 Cortisol metabolism in human obesity: impaired cortisone–cortisol conversion in subjects with central adiposity. Journal of Clinical Endocrinology and Metabolism 84 1022–1027.
Tomlinson JW, Sinha B, Bujalska I, Hewison M & Stewart PM 2002 Expression of 11 beta-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. Journal of Clinical Endocrinology and Metabolism 87 5630–5635.
Voice MW, Seckl JR, Edwards CR & Chapman KE 1996 11ß-Hydroxysteroid dehydrogenase type 1 expression in 2S FAZA hepatoma cells is hormonally regulated: a model system for the study of hepatic glucocorticoid metabolism. Biochemistry 317 621–625.
Wake DJ, Rask E, Livingstone DE, Soderberg S, Olsson T & Walker BR 2003 Local and systemic impact of transcriptional up-regulation of 11 beta-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. Journal of Clinical Endocrinology and Metabolism 88 3983–3988.
Walker EA, Clark AM, Hewison M, Ride JP & Stewart PM 2001 Functional expression, characterization, and purification of the catalytic domain of human 11-beta -hydroxysteroid dehydrogenase type 1. Journal of Biological Chemistry 276 21343–21350.
Williams LJ, Lyons V, MacLeod I, Rajan V, Darlington GJ, Poli V, Seckl JR & Chapman KE 2000 C/EBP regulates hepatic transcription of 11 beta -hydroxysteroid dehydrogenase type 1. A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways. Journal of Biological Chemistry 275 30232–30239.
Received 18 January 2005
Accepted 27 January 2005
This article has been cited by other articles:
|
|
 |
|
  J. W. Tomlinson, J. Finney, C. Gay, B. A. Hughes, S. V. Hughes, and P. M. Stewart Impaired Glucose Tolerance and Insulin Resistance Are Associated With Increased Adipose 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Expression and Elevated Hepatic 5{alpha}-Reductase Activity Diabetes, October 1, 2008; 57(10): 2652 - 2660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Senesi, P. Marcolongo, I. Manini, R. Fulceri, V. Sorrentino, M. Csala, G. Banhegyi, and A. Benedetti Constant expression of hexose-6-phosphate dehydrogenase during differentiation of human adipose-derived mesenchymal stem cells J. Mol. Endocrinol., September 1, 2008; 41(3): 125 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Balachandran, H. Guan, M. Sellan, S. van Uum, and K. Yang Insulin and Dexamethasone Dynamically Regulate Adipocyte 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Endocrinology, August 1, 2008; 149(8): 4069 - 4079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. Bujalska, K. N. Hewitt, D. Hauton, G. G. Lavery, J. W. Tomlinson, E. A. Walker, and P. M. Stewart Lack of Hexose-6-Phosphate Dehydrogenase Impairs Lipid Mobilization from Mouse Adipose Tissue Endocrinology, May 1, 2008; 149(5): 2584 - 2591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. De Sousa Peixoto, S. Turban, J. H. Battle, K. E. Chapman, J. R. Seckl, and N. M. Morton Preadipocyte 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Is a Keto-Reductase and Contributes to Diet-Induced Visceral Obesity in Vivo Endocrinology, April 1, 2008; 149(4): 1861 - 1868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Lavery, E. A. Walker, N. Turan, D. Rogoff, J. W. Ryder, J. M. Shelton, J. A. Richardson, F. Falciani, P. C. White, P. M. Stewart, et al. Deletion of Hexose-6-phosphate Dehydrogenase Activates the Unfolded Protein Response Pathway and Induces Skeletal Myopathy J. Biol. Chem., March 28, 2008; 283(13): 8453 - 8461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Gomez-Sanchez, D. G. Romero, A. F. de Rodriguez, M. P. Warden, Z. Krozowski, and C. E. Gomez-Sanchez Hexose-6-Phosphate Dehydrogenase and 11{beta}-Hydroxysteroid Dehydrogenase-1 Tissue Distribution in the Rat Endocrinology, February 1, 2008; 149(2): 525 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Lavery, D. Hauton, K. N. Hewitt, S. M. Brice, M. Sherlock, E. A. Walker, and P. M. Stewart Hypoglycemia with Enhanced Hepatic Glycogen Synthesis in Recombinant Mice Lacking Hexose-6-Phosphate Dehydrogenase Endocrinology, December 1, 2007; 148(12): 6100 - 6106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. London, G. Lala, R. Berger, A. Panzenbeck, A. A. Kohli, M. Renner, A. Jackson, T. Raynor, K. Loya, and T. W. Castonguay Sucrose Access Differentially Modifies 11{beta}-Hydroxysteroid Dehydrogenase-1 and Hexose-6-Phosphate Dehydrogenase Message in Liver and Adipose Tissue in Rats J. Nutr., December 1, 2007; 137(12): 2616 - 2621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Barat, D. E. W. Livingstone, C. M. C. Elferink, C. R. McDonnell, B. R. Walker, and R. Andrew Effects of Gonadectomy on Glucocorticoid Metabolism in Obese Zucker Rats Endocrinology, October 1, 2007; 148(10): 4836 - 4843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Rogoff, J. W. Ryder, K. Black, Z. Yan, S. C. Burgess, D. R. McMillan, and P. C. White Abnormalities of Glucose Homeostasis and the Hypothalamic-Pituitary-Adrenal Axis in Mice Lacking Hexose-6-Phosphate Dehydrogenase Endocrinology, October 1, 2007; 148(10): 5072 - 5080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. W. Yau, K. M. McNair, J. Noble, D. Brownstein, C. Hibberd, N. Morton, J. J. Mullins, R. G. M. Morris, S. Cobb, and J. R. Seckl Enhanced Hippocampal Long-Term Potentiation and Spatial Learning in Aged 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Knock-Out Mice J. Neurosci., September 26, 2007; 27(39): 10487 - 10496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Walker, A. Ahmed, G. G. Lavery, J. W. Tomlinson, S. Y. Kim, M. S. Cooper, J. P. Ride, B. A. Hughes, C. H. L. Shackleton, P. McKiernan, et al. 11beta-Hydroxysteroid Dehydrogenase Type 1 Regulation by Intracellular Glucose 6-Phosphate Provides Evidence for a Novel Link between Glucose Metabolism and Hypothalamo-Pituitary-Adrenal Axis Function J. Biol. Chem., September 14, 2007; 282(37): 27030 - 27036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Chandras, T E Harris, A L. Bernal, D R E Abayasekar |
